Listen
Reason for request
Inclusion on the list of medicines refundable by National Health Insurance (B/56 only) and approved for hospital use (B/56 and B/100) in the extension of indication: “Treatment of chronic heart failure: Ivabradine is indicated in the treatment of chronic heart failure, NYHA class II to IV with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated”.
-
Clinical Benefit
| Substantial |
The actual benefit of these proprietary medicinal products is substantial. |
Clinical Added Value
| minor |
Taking into account the results of the SHIFT study, PROCORALAN offers a minor |
| no clinical added value |
In other patients, PROCORALAN does not offer any improvement in actual benefit (IAB V). |
English version
Contact Us
Évaluation des médicaments
